| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel;
Department of Molecular Microbiology and Biotechnology, Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv, Israel; and
Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
Tumor-associated, MHC-restricted peptides, recognized by tumor-specific CD8+ lymphocytes, are desirable targets for novel approaches in immunotherapy because of their highly restricted fine specificity. Abs that recognize these tumor-associated MHC-peptide complexes, with the same specificity as TCR, would therefore be valuable reagents for studying Ag presentation by tumor cells, for visualizing MHC-peptide complexes on cells, and eventually for developing new targeting agents for cancer immunotherapy. To generate molecules with such a unique, fine specificity, we immunized HLA-A2 transgenic mice with a single-chain HLA-A2, complexed with a common antigenic T cell HLA-A2-restricted epitope derived from the melanoma differentiation Ag gp100. Using a phage display approach, we isolated a recombinant scFv Ab that exhibits a characteristic TCR-like binding specificity, yet, unlike TCRs, it did so with a high affinity in the nanomolar range. The TCR-like Ab can recognize the native MHC-peptide complex expressed on the surface of APCs, and on peptide-pulsed or native melanoma cells. Moreover, when fused to a very potent cytotoxic effector molecule in the form of a truncated bacterial toxin, it was able to specifically kill APCs in a peptide-dependent manner. These results demonstrate the utility of high affinity TRC-like scFv recombinant Abs directed toward human cancer T cell epitopes. Such TCR-like Abs may prove to be very useful for monitoring and visualizing the expression of specific MHC-peptide complexes on the surface of tumor cells, APCs, and lymphoid tissues, as well as for developing a new family of targeting agents for immunotherapy.
This article has been cited by other articles:
|
|
 |
|
  M. A. Purbhoo, Y. Li, D. H. Sutton, J. E. Brewer, E. Gostick, G. Bossi, B. Laugel, R. Moysey, E. Baston, N. Liddy, et al. The HLA A*0201-restricted hTERT540-548 peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor Mol. Cancer Ther., July 1, 2007; 6(7): 2081 - 2091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Oved, O. Ziv, J. Jacob-Hirsch, R. Noy, H. Novak, O. Makler, D. Galit, S. Keren, D. Segal, C. Gefen-Dor, et al. A Novel Postpriming Regulatory Check Point of Effector/Memory T Cells Dictated through Antigen Density Threshold-Dependent Anergy J. Immunol., February 15, 2007; 178(4): 2307 - 2317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Weidanz, T. Nguyen, T. Woodburn, F. A. Neethling, M. Chiriva-Internati, W. H. Hildebrand, and J. Lustgarten Levels of Specific Peptide-HLA Class I Complex Predicts Tumor Cell Susceptibility to CTL Killing J. Immunol., October 15, 2006; 177(8): 5088 - 5097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. P. Wittman, D. Woodburn, T. Nguyen, F. A. Neethling, S. Wright, and J. A. Weidanz Antibody Targeting to a Class I MHC-Peptide Epitope Promotes Tumor Cell Death J. Immunol., September 15, 2006; 177(6): 4187 - 4195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Mosquera, K. F. Card, S. A. Price-Schiavi, H. J. Belmont, B. Liu, J. Builes, X. Zhu, P.-A. Chavaillaz, H.-i. Lee, J.-a. Jiao, et al. In Vitro and In Vivo Characterization of a Novel Antibody-Like Single-Chain TCR Human IgG1 Fusion Protein J. Immunol., April 1, 2005; 174(7): 4381 - 4388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Levy and A. P. Levy ELISA for Determination of the Haptoglobin Phenotype Clin. Chem., November 1, 2004; 50(11): 2148 - 2150. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
